Federal Policy
Trump Announces 100% Tariff on Imported Generics Effective August 2028
President Trump announced Tuesday via social media that imported generic drugs will face a 100 percent tariff beginning in August 2028 unless manufacturers relocate production to the United States. The tariff is described as a penalty designed to reshore generic pharmaceutical manufacturing. Generic drugs constitute the majority of Medicaid pharmacy spending, and most generics dispensed in the U.S. are manufactured overseas or contain active pharmaceutical ingredients from foreign suppliers. The two-year implementation timeline provides MCOs and state programs time to assess potential pharmacy cost impacts and supply chain disruptions.
Why it mattersMedicaid managed care organizations face potential pharmacy cost increases and drug supply disruptions if generic manufacturers do not reshore production or pass tariff costs through rebates and pricing, requiring pharmacy benefit strategy adjustments and state contract renegotiations.